TY - JOUR T1 - Prevention of cardiovascular disease and renal failure in type 2 diabetes: sodium-glucose cotransporter-2 (SGLT2) inhibitors JF - BMJ Evidence-Based Medicine JO - BMJ EBM DO - 10.1136/bmjebm-2019-111231 SP - bmjebm-2019-111231 AU - Jack W O’Sullivan Y1 - 2019/07/30 UR - http://ebm.bmj.com/content/early/2019/09/05/bmjebm-2019-111231.abstract N2 - End-stage renal failure is a common and devastating consequence of type 2 diabetes. Sodium-glucose cotransporter-2 (SGLT2) inhibitors, in combination with angiotensin-converting enzyme inhibitors (ACEI) and angiotensin II receptor antagonists (ARBs), reduce cardiovascular events and deterioration of renal disease in patients with type 2 diabetes and renal impairment. Type 2 diabetes is a global epidemic.1 It is the third most frequent cause of disability in high-income countries and the most common cause in most low-income countries.1 Much of this disability relates from renal impairment caused by uncontrolled blood glucose levels; as many as 40% of patients with diabetes will develop kidney disease.2 The presence of renal impairment in patients with type 2 diabetes has many consequences—chiefly, these patients are at substantial risk of cardiovascular disease and, often in <10 years, progress to end-stage renal failure.3 Currently, the only medicines approved for renoprotective in patients with diabetes are renin–angiotensin blockers, namely ACEI and ARBs.4 The CREDENCE trial tested the effect of … ER -